RxDoctor Payments Data

Stanley Tao, MD

Ophthalmology · Toledo, OHNPI 1811934805

Payments from drug & device makers

$12,525in general payments, 2019–2025

Across 165 payments — averaging $75.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Alimera Sciences, Inc.$3K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Regeneron$372
  • Genentech USA, Inc.$283
  • Astellas Pharma US Inc$220
  • plus $494 from 12 others

What the payments were for

  • Consulting fees$6,00048%
  • Travel & lodging$651%
  • Food & beverage$6,44151%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,525 in reported general payments places this provider in the 85th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$1,820,557
Medicare patients
1,174
Services billed
8,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine39$33,340
Brimonidine Tartrate127$15,520
Latanoprost750$10,304
Cyclosporine13$10,232
Prednisolone Acetate274$7,846
SimbrinzaBrinzolamide/Brimonidine Tart28$7,741
LumiganBimatoprost22$7,407
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha257$4,255
Brinzolamide12$3,214
Bimatoprost29$2,794
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$2,288
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat154$2,202
Travoprost13$2,068
Timolol Maleate149$1,966
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim126$795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$6,563$40,74761 claims
AlconSimbrinza$111$7,74128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →